AU2016389495B2 - Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof - Google Patents

Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof Download PDF

Info

Publication number
AU2016389495B2
AU2016389495B2 AU2016389495A AU2016389495A AU2016389495B2 AU 2016389495 B2 AU2016389495 B2 AU 2016389495B2 AU 2016389495 A AU2016389495 A AU 2016389495A AU 2016389495 A AU2016389495 A AU 2016389495A AU 2016389495 B2 AU2016389495 B2 AU 2016389495B2
Authority
AU
Australia
Prior art keywords
rna
cells
transgene
promoter
recombinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016389495A
Other languages
English (en)
Other versions
AU2016389495A1 (en
Inventor
Joshua BREUNIG
Moise Danielpour
Gi Bum Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of AU2016389495A1 publication Critical patent/AU2016389495A1/en
Application granted granted Critical
Publication of AU2016389495B2 publication Critical patent/AU2016389495B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2016389495A 2016-01-26 2016-12-30 Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof Active AU2016389495B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287197P 2016-01-26 2016-01-26
US62/287,197 2016-01-26
PCT/US2016/069442 WO2017131926A1 (en) 2016-01-26 2016-12-30 SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF

Publications (2)

Publication Number Publication Date
AU2016389495A1 AU2016389495A1 (en) 2018-08-16
AU2016389495B2 true AU2016389495B2 (en) 2023-03-30

Family

ID=59398838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016389495A Active AU2016389495B2 (en) 2016-01-26 2016-12-30 Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof

Country Status (8)

Country Link
US (2) US11466290B2 (enExample)
EP (1) EP3408396A4 (enExample)
JP (3) JP2019511243A (enExample)
KR (1) KR102811061B1 (enExample)
CN (1) CN108884472A (enExample)
AU (1) AU2016389495B2 (enExample)
CA (2) CA3303511A1 (enExample)
WO (1) WO2017131926A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3303511A1 (en) 2016-01-26 2026-05-13 Cedars-Sinai Medical Center SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
AU2019236288B2 (en) 2018-03-16 2025-06-05 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
CN109321599B (zh) * 2018-09-27 2023-08-22 同济大学 人多能干细胞中的谱系示踪系统的构建与应用
CN109943564B (zh) * 2019-03-28 2022-03-15 上海市中医老年医学研究所 Amh基因定点敲入2A-Cre的杂合子小鼠模型构建方法及其应用
EP3983000A4 (en) * 2019-06-17 2023-10-11 Cedars-Sinai Medical Center SYSTEMS AND METHODS OF DOUBLE RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) IN VIVO AND ASSOCIATED DISEASE MODELS
CA3140297A1 (en) * 2019-06-19 2020-12-24 Simon Auslaender Method for the generation of a protein expressing cell by targeted integration using cre mrna
CN119301241A (zh) 2022-06-06 2025-01-10 协和发酵生化株式会社 提高了3'-唾液酸乳糖的生产率的微生物和3'-唾液酸乳糖的制造方法
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2026050378A1 (en) * 2024-08-28 2026-03-05 Cedars-Sinai Medical Center Humanized genetically-engineered autochthonous brain tumors compatible with use in immunocompetent rodents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001247A2 (en) * 2009-06-29 2011-01-06 University Of Basel Methods and kits for high efficiency engineering of conditional mouse alleles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003020743A1 (en) * 2001-09-05 2003-03-13 Regeneron Pharmaceuticals, Inc. Methods of expressing transgenes
WO2003090689A2 (en) 2002-04-25 2003-11-06 Wisconsin Alumni Research Foundation Neurodegenerative disorder treatment using gdnf secreting neural cells
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
CA2672203A1 (en) * 2006-12-21 2008-07-03 Genentech, Inc. Compositions and methods for the expression of nucleic acids
US8592211B2 (en) 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
US9528124B2 (en) * 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2014127289A1 (en) 2013-02-15 2014-08-21 International Stem Cell Corporation Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases
SG11201507829SA (en) 2013-03-21 2015-12-30 Univ Kyoto Pluripotent stem cell for neuronal differentiation induction
ES2777217T3 (es) * 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
US9694036B2 (en) 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2015139093A1 (en) 2014-03-21 2015-09-24 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
EP3122370A1 (en) 2014-03-28 2017-02-01 Buck Institute for Research on Aging Methods and compositions for modulating the immune system
EP3584312A1 (en) 2014-06-27 2019-12-25 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus e4orf1, and methods of making and using the same
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CA3303511A1 (en) 2016-01-26 2026-05-13 Cedars-Sinai Medical Center SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
AU2019236288B2 (en) 2018-03-16 2025-06-05 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
EP3983000A4 (en) 2019-06-17 2023-10-11 Cedars-Sinai Medical Center SYSTEMS AND METHODS OF DOUBLE RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) IN VIVO AND ASSOCIATED DISEASE MODELS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001247A2 (en) * 2009-06-29 2011-01-06 University Of Basel Methods and kits for high efficiency engineering of conditional mouse alleles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OSTERWALDER: "Genome-wide identification of Hand2 target regions in mouse embryos using dRMCE, a new genetic tool", PHD THESIS, 2012, pages 37, XP055402778, Retrieved from the Internet [retrieved on 20170305] *

Also Published As

Publication number Publication date
KR20180101535A (ko) 2018-09-12
JP2019511243A (ja) 2019-04-25
CA3303511A1 (en) 2026-05-13
US11466290B2 (en) 2022-10-11
EP3408396A4 (en) 2019-10-09
CN108884472A (zh) 2018-11-23
US20190390222A1 (en) 2019-12-26
AU2016389495A1 (en) 2018-08-16
WO2017131926A1 (en) 2017-08-03
US20230084201A1 (en) 2023-03-16
KR102811061B1 (ko) 2025-05-21
EP3408396A1 (en) 2018-12-05
CA3012042A1 (en) 2017-08-03
JP2022091801A (ja) 2022-06-21
JP2024063065A (ja) 2024-05-10

Similar Documents

Publication Publication Date Title
US20230084201A1 (en) SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
Kanca et al. An efficient CRISPR-based strategy to insert small and large fragments of DNA using short homology arms
Kim et al. Rapid generation of somatic mouse mosaics with locus-specific, stably integrated transgenic elements
Lampreht Tratar et al. Transgenic mouse models in cancer research
US20220304286A1 (en) SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
Veltrop et al. A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
JP6279562B2 (ja) 条件付きノックアウト対立遺伝子を生成するための方法および組成物
JP5320546B2 (ja) Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム
US20160186208A1 (en) Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
Tasic et al. Extensions of MADM (mosaic analysis with double markers) in mice
AU2017313912A1 (en) Methods of editing DNA methylation
JP7418796B2 (ja) 細胞株の開発のための相同組換えベクターの高速生成のためのｄｎａプラスミド
Wu et al. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells
Shin et al. In vivo gene correction with targeted sequence substitution through microhomology-mediated end joining
Brandner Rodent models of tumours of the central nervous system
Simmons et al. Pou4f2 knock-in Cre mouse: A multifaceted genetic tool for vision researchers
US20230069642A1 (en) Precise template-free correction of brca1 mutation in human cells via genome editing
Kim et al. Generating in vivo somatic mouse mosaics with locus-specific, stably-integrated transgenic elements
Linesch et al. Tetracycline‐Inducible and Reversible Stable Gene Expression in Human iPSC‐Derived Neural Progenitors and in the Postnatal Mouse Brain
Chambers et al. Sequential gene targeting to make chimeric tumor models with de novo chromosomal abnormalities
US20180291375A1 (en) Ets factors regulate neural stem cell depletion and gliogenesis in ras pathway glioma
Sachan et al. 22 Inducible CRISPR-based Genome Editing for the Characterization of Cancer Genes
Leong An inducible and reversible genetics platform for novel drug target discovery
Liu Ngn3-expressing progenitor heterogeneity drives endocrine lineage allocation in pancreas development
Larson Characterization Of The Primitive Neuroectodermal Tumor Genome Using Transposon-Mediated Insertional Mutagenesis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)